Scandion Oncology

Scandion Oncology har bevakats av Redeye. Här är samtliga 11 artiklar vi kopplat till bolaget.

Analytiker som bevakat bolaget

Bevisnivån visar vad som är belagt om att bolaget betalat för bevakningen, för varje analytiker för sig. Utfallet är kursutvecklingen sedan analytikerns första publicering .

Analytiker som bevakat Scandion Oncology, med period, antal publiceringar och utfall.
Analytiker	Period	Publiceringar	Bevisnivå	Utfall
Redeye	2021-05-17 –2024-11-12	11	Upprepad bevakning	−99,6 %

Klicka på en analytiker för hela uträkningen: kurs vid start, årsmärken och källor.

Kapitalanskaffning och aktörer

Enligt bolagets egna pressmeddelanden, prospekt och årsredovisningar; varje uppgift har en källa. Regler och begränsningar står på metodsidan.

Sökt efter Redeye AB, Redeye Nordic Growth AB och Redeye Sweden AB i hela texten i alla 234 pressmeddelanden i bolagets arkiv hos MFN, oktober 2018–juni 2025. En roll hittades och står nedan. Arkivet

Alla aktieemissioner och units har sökts i alla 234 pressmeddelanden i bolagets arkiv hos MFN, oktober 2018–juni 2025. 7 emissioner hittades och står nedan. Konvertibler och obligationer ingår inte. Arkivet

Övriga aktörer är inte undersökta.

Finansiella rådgivare: Redeye AB juli 2022

Emissioner 7

Period: 2018–2024
Tillfört kapital: 409 MSEKalla emissioner anger beloppet
Beräknad garantiersättning: 18,21 MSEK beräknad: belopp × kontant procentsats, för 1 garanti där båda står i källan

Datum: 20 november 2024Typ: Inlösen av teckningsoptionerSökt: 17,2Tillfört: 0,3Teckningskurs: 0,12 SEKGaranti: ej angivet

Sökt: 17,2 MSEK
Tillfört: 0,3 MSEK
Teckningskurs: 0,12 SEK per aktie

Utnyttjande av 2 833 532 teckningsoptioner serie TO 2 (cirka 2,0 procent av de utestående) som getts ut som en del av unitsen i företrädesemissionen i juni 2024. Lösenkursen sattes till 70 procent av den volymviktade kursen 16-29 oktober 2024. Antalet aktier ökar med 2 833 532 och aktiekapitalet med 208 264,60 DKK. Beloppet vid fullt utnyttjande, 17,2 MSEK, anges i rättelsen 2024-10-31 (det ursprungliga meddelandet 2024-10-30 angav 15,8 MSEK).

Ej angivet i källan: varav kvittning, emissionskostnad, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.

Källor och citat (2 källor)

Datumon 20 November 2024, at 17.30 CETWarrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million 2024-11-20
TypIn total, 2,833,532 warrants of series TO 2 were exercised for subscription of 2,833,532 sharesWarrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million 2024-11-20
Sökt beloppif all the warrants of series TO 2 are exercised, the Company will receive approximately SEK 17,2 million before issue costs rather than the previously stated SEK 15,8 millionCorrection: Scandion Oncology announces exercise price for warrants of series TO 2 2024-10-31
TillförtScandion will thus receive approximately SEK 0.3 million before issuing costs.Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million 2024-11-20
Teckningskursat an exercise price of SEK 0.12 per shareWarrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million 2024-11-20
Uppläggthe share capital in the Company will increase with DKK 208,264.6020 through the issuance of 2,833,532 new sharesWarrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million 2024-11-20
UppläggWithin the rights issue, a total of 143,416,179 warrants of series TO 2 were issued.Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million 2024-11-20

Datum: 25 juni 2024Typ: Företrädesemission av unitsSökt: 60,8Tillfört: 30,6Teckningskurs: 0,64 SEK per unitGaranti: Garanti 49,6 %, garanterna tecknade 10,3 %

Sökt: 60,8 MSEK
Tillfört: 30,6 MSEK
Teckningskurs: 0,64 SEK per unit

Garanti: 30,2 MSEK, 49,6 % av emissionen · garanterna tecknade 10,3 % av emissionen

Garanter: Befintliga ägare; Externa investerare

Ej angivet i källan: ersättning.

Företrädesemission av units: varje unit omfattar fyra aktier, tre teckningsoptioner serie TO 2 och en serie TO 3. Sju uniträtter per aktie, tre uniträtter per unit; högst 94 982 934 units. Utfallet var 34 278 619 units (cirka 36,1 procent) med uniträtter, 3 698 922 (cirka 3,9 procent) utan uniträtter och 9 827 852 (cirka 10,3 procent) av garanterna, totalt 47 805 393 units (cirka 50,3 procent), motsvarande 191 221 572 nya aktier. Teckningsåtaganden på cirka 0,4 MSEK ingår i den tecknade delen och är ingen garanti. Registrerad hos Erhvervsstyrelsen 2024-07-11. Beslutet 2024-04-19 var villkorat av bolagsstämmans bemyndigande 2024-05-06.

Ej angivet i källan: varav kvittning, emissionskostnad. Inte undersökt: finansiell rådgivare, emissionsinstitut.

Källor och citat (3 källor)

Datumon 25 June 2024, at 17.30 CESTSCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE 2024-06-25
Typannounces the outcome of the rights issue of units that was announced on 19 April 2024SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE 2024-06-25
Sökt beloppif fully subscribed, provide Scandion with initial proceeds of up to approximately SEK 60.8 million before issue costsSCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE 2024-05-23
TillförtThrough the Rights Issue, Scandion will initially receive approximately SEK 30.6 million before issue costsSCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE 2024-06-25
TeckningskursThe subscription price has been set to SEK 0.64 per UnitSCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE 2024-05-23
Garanti: belopp, garanti: andelunderwriting commitments of approximately SEK 30.2 million from existing shareholders and external investors, corresponding to approximately 49.6 per cent of the Rights IssueSCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE 2024-05-23
Garanti: tecknat av garanterna9,827,852 units, corresponding to approximately 10.3 percent of the Rights Issue, was subscribed for by underwritersSCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE 2024-06-25
Garanti: garanterunderwriting commitments of approximately SEK 30.2 million from existing shareholders and external investorsSCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE 2024-05-23
UppläggEach unit consists of four (4) shares, three (3) warrants of series TO 2 and one (1) warrant of series TO 3.SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE 2024-06-25
UppläggIn total, a maximum of 94,982,934 Units will be issued.SCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE 2024-05-23
UppläggThe Rights Issue is thus subscribed to a total of approximately 50.3 percent.SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE 2024-06-25
Uppläggthe share capital increase and updated articles of association have been registered with the Danish Business AuthoritySCANDION ONCOLOGY'S RIGHTS ISSUE REGISTERED WITH THE DANISH BUSINESS AUTHORITY 2024-07-11

Datum: 1 juli 2022Typ: FöreträdesemissionSökt: 93,7Tillfört: 75Teckningskurs: 8,75 SEKGaranti: Garanti 80 %, garanterna tecknade 66,5 %

Sökt: 93,7 MSEK
Tillfört: 75 MSEK
Teckningskurs: 8,75 SEK per aktie
Emissionskostnad: 17 MSEK
Finansiell rådgivare: Redeye AB

Garanti: 80 % av emissionen · garanterna tecknade 66,5 % av emissionen

Garanter: Befintliga ägare; Externa investerare

Ej angivet i källan: belopp, ersättning.

Företrädesemission av högst 10 711 848 aktier. Utfallet var 1 396 886 aktier (cirka 13 procent) tecknade med företrädesrätt, 55 750 aktier (cirka 0,5 procent) utan företrädesrätt och 7 118 792 aktier (cirka 66,5 procent) av garanterna; totalt cirka 80 procent. Datum är det preliminära utfallet 2022-07-01, som redan anger vad som tecknats; slutligt utfall följde 2022-07-04 och registreringen 2022-07-26. Faktisk kostnad anges i DKK (11 058 TDKK i årsredovisningen 2022) och är inte omräknad; beloppet i fältet kostnad är bolagets uppskattning vid full teckning.

Ej angivet i källan: varav kvittning. Inte undersökt: emissionsinstitut.

Källor och citat (4 källor)

DatumThe information was submitted for publication, through the agency of the contact person set out above, at 22:00 CET on July 1, 2022.Scandion Oncology announces preliminary outcome of its rights issue 2022-07-01
Typresolved on an issue of shares with preferential rights for existing shareholdersScandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million 2022-06-01
Sökt beloppIn the event of full subscription, the Rights Issue will provide Scandion with approximately SEK 93.7 million before deduction of issue costs.Scandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million 2022-06-01
TillförtThrough the Rights Issue, Scandion raises approx. SEK 75 million before deduction of issue related costs.Scandion Oncology announces final outcome of its rights issue 2022-07-04
TeckningskursSubscription price: SEK 8.75 per share.Scandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million 2022-06-01
EmissionskostnadPreliminary transaction related costs are approximately SEK 17 million.Scandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million 2022-06-01
Finansiell rådgivareRedeye AB acts as financial adviser and Horten Advokatpartnerselskab (as to Danish law) and Advokatfirman Schjødt (as to Swedish law) act as legal advisers in connection with the Rights Issue.Scandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million 2022-06-01
Garanti: andel, garanti: garanterThe Rights Issue is covered by subscription and guarantee commitments from principal owners and new investors corresponding to approximately 80% of the issue proceeds.Scandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million 2022-06-01
Garanti: tecknat av garanterna7,118,792 shares, corresponding to approx. 66.5% of the Rights Issue, were subscribed for by guarantors.Scandion Oncology announces final outcome of its rights issue 2022-07-04
UppläggThe Rights Issue comprised a maximum of 10,711,848 ordinary shares.Scandion Oncology announces preliminary outcome of its rights issue 2022-07-01
UppläggExpenses related to capital increase -11,058 0Scandion Oncology Annual Report 2022 2023-03-28

Datum: 15 december 2020Typ: FöreträdesemissionSökt: 235,661Tillfört: 236Teckningskurs: 22 SEKGaranti: Garanti 86 %, garanterna tecknade 51 %

Sökt: 235,661 MSEK
Tillfört: 236 MSEK
Teckningskurs: 22 SEK per aktie
Emissionskostnad: 36 MSEK

Garanti: 202,3 MSEK, 86 % av emissionen · ersättning 9 % kontant · garanterna tecknade 51 % av emissionen · beräknad kontant ersättning 18,21 MSEK (belopp × kontant procentsats)

Garanter: Externa investerare

Företrädesemission av 10 711 848 nya aktier, en teckningsrätt per aktie och två teckningsrätter per ny aktie. Fulltecknad: 34 procent med uniträtter, 15 procent utan (varav 12 procent av externa professionella investerare) och 51 procent av garanterna. Teckningsåtaganden på cirka 29 MSEK från externa professionella investerare är ingen garanti. Emissionen registrerades hos Erhvervsstyrelsen 2021-01-06. Aktieantalet ökade från 21 423 696 till 32 135 544. Kostnaden 36 MSEK är bolagets uppskattning i prospektet, som utfallets tillägg upprepar.

Ej angivet i källan: varav kvittning. Inte undersökt: finansiell rådgivare, emissionsinstitut.

Källor och citat (5 källor)

Datum2020-12-15 08:49:27SCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE 2020-12-15
Typresolved on a fully guaranteed new share issue of 10,711,848 shares with preferential rights for the Company's existing shareholdersThe Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million 2020-11-16
Sökt beloppThe Company will receive SEK 235,660,656 before deduction of transaction costs related to the Rights IssueThe Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million 2020-11-16
Tillförtprovides Scandion with proceeds amounting to approximately SEK 236 million before issue costsSCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE 2020-12-15
TeckningskursThe subscription price in the Rights Issue is SEK 22 per shareThe Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million 2020-11-16
EmissionskostnadThe issue costs amount to approximately SEK 36 millionScandion Oncology: Supplement to previously published press release regarding the outcome of Scandion Oncology’s rights issue 2020-12-15
Garanti: belopp, garanti: garanterguarantee commitments amounting to approximately SEK 202.3 million from certain external guarantorsThe Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million 2020-11-16
Garanti: andelthe Company has received approximately 86 per cent guarantee commitments from external professional investors and is thus fully guaranteed.Scandion Oncology publishes prospectus relating to the rights issue and announces the intention of changing listing venue to Nasdaq First North Growth Market Sweden 2020-11-24
Garanti: kontant ersättningA guarantee commission will be paid for the guarantee commitments, based on current market conditions, of nine (9) percent of the guaranteed amount in cash consideration.The Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million 2020-11-16
Garanti: tecknat av garanternacorresponding to 5,477,437 shares or approximately 51 percent, were subscribed for by the guarantorsSCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE 2020-12-15
UppläggThe number of shares in the Company will increase by 10,711,848 shares to a total of 32,135,544 sharesSCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE 2020-12-15
Upplägg3,600,363 shares, corresponding to 34 percent of the Rights Issue, were subscribed for using subscription rightsSCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE 2020-12-15
Uppläggsubscription commitments (without commitment fee) amounting to approximately SEK 29 million from external professional investorsThe Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million 2020-11-16
Uppläggthe share capital increase and updated articles of association have been registered with the Danish Business AuthorityScandion Oncology’s rights issue registered with the Danish Business Authority – BTAs are converted to shares 2021-01-06

Datum: 6 oktober 2020Typ: Inlösen av teckningsoptionerSökt: 12,4Tillfört: 12,3Teckningskurs: 5,2 SEKGaranti: ej angivet

Sökt: 12,4 MSEK
Tillfört: 12,3 MSEK
Teckningskurs: 5,2 SEK per aktie
Emissionskostnad: 1,1 MSEK

Utnyttjande av teckningsoptioner serie TO 1, utgivna med företrädesemissionen av units 2019, under utnyttjandeperioden 10 september-1 oktober 2020. 2 371 455 optioner utnyttjades, cirka 99,6 procent. Aktieantalet ökade från 19 052 241 till 21 423 696 när aktierna registrerats. Kostnaden 1,1 MSEK är bolagets uppskattning i utfallsmeddelandet.

Ej angivet i källan: varav kvittning, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.

Källor och citat (2 källor)

Datum2020-10-06 09:05:44Scandion Oncology receives approximately MSEK 12.3 through successful warrant exercise 2020-10-06
Typ2,371,455 TO 1 were exercisedScandion Oncology receives approximately MSEK 12.3 through successful warrant exercise 2020-10-06
Sökt beloppScandion Oncology will be allocated approximately SEK 12.4 million (before costs)The exercise period for warrants in Scandion Oncology A/S begins today 2020-09-10
TillförtScandion Oncology is thus provided with a total of approximately MSEK 12.3 before issue costsScandion Oncology receives approximately MSEK 12.3 through successful warrant exercise 2020-10-06
Teckningskursto subscribe for one regular new share in Scandion Oncology for SEK 5.20 per shareThe exercise period for warrants in Scandion Oncology A/S begins today 2020-09-10
EmissionskostnadThe issue costs are estimated to amount to approximately MSEK 1.1Scandion Oncology receives approximately MSEK 12.3 through successful warrant exercise 2020-10-06
Uppläggthe total number of shares will amount to 21,423,696Scandion Oncology receives approximately MSEK 12.3 through successful warrant exercise 2020-10-06
Uppläggcorresponding to a subscription rate of approximately 99.6 percent of the total number of outstanding TO 1Scandion Oncology receives approximately MSEK 12.3 through successful warrant exercise 2020-10-06

Datum: 12 juli 2019Typ: Företrädesemission av unitsSökt: 29,3Tillfört: 29,3Teckningskurs: 12,3 SEK per unitGaranti: Garanti, användes inte

Sökt: 29,3 MSEK
Tillfört: 29,3 MSEK
Teckningskurs: 12,3 SEK per unit
Emissionskostnad: 3,8 MSEK

Toppgaranti: 7,2 MSEK · garantin användes inte

Garanter: Garanter ej angivna i källan

Ej angivet i källan: andel, ersättning.

Företrädesemission av units; varje unit omfattade tre nya aktier och en vederlagsfri teckningsoption serie TO 1 (utnyttjad i september-oktober 2020). Högst 7 144 590 aktier och 2 381 530 optioner. Tecknades till cirka 199 procent (58,3 MSEK exklusive garantiåtaganden); 2 214 691 units (cirka 93 procent) tecknades med uniträtter. Teckningsåtaganden på 18,9 MSEK är ingen garanti. 7 144 590 nya aktier emitterades; aktieantalet ökade från 11 907 651 till 19 052 241. Garantin om 7,2 MSEK var "top-down" och aktiverades inte. Kostnaden 3,8 MSEK är bolagets uppskattning i utfallsmeddelandet.

Ej angivet i källan: varav kvittning. Inte undersökt: finansiell rådgivare, emissionsinstitut.

Källor och citat (3 källor)

Datum2019-07-12 10:34:52Significantly oversubscribed rights issue in Scandion Oncology 2019-07-12
Typrights issue of units endedSignificantly oversubscribed rights issue in Scandion Oncology 2019-07-12
Sökt beloppThe capitalization consists of shares amounting to a maximum of approximately SEK 29.3 millionThe board of Scandion Oncology proposes a rights issue to increase the commercial potential for its drug candidates and to expand its drug pipeline 2019-05-27
TillförtScandion Oncology will now be provided approx. SEK 29.3 million before issue costsSignificantly oversubscribed rights issue in Scandion Oncology 2019-07-12
TeckningskursIssue price: 12.30 SEK per unit, corresponding to 4.10 SEK per shareScandion Oncology A/S publishes prospectus in connection with rights issue 2019-06-17
Emissionskostnadissue costs, which are estimated to amount to approx. SEK 3.8 million (12.8% of the issue volume) of which approx. SEK 0.7 million refers to guarantee compensationSignificantly oversubscribed rights issue in Scandion Oncology 2019-07-12
Toppgaranti: beloppTop-down guarantee commitments of approximately SEK 7.2 millionScandion Oncology A/S publishes prospectus in connection with rights issue 2019-06-17
Toppgaranti: tecknat av garanternaDue to the extensive interest, guarantee commitments are not activated.Significantly oversubscribed rights issue in Scandion Oncology 2019-07-12
Toppgaranti: garanterfrom institutional and private investors totaling approximately 82 percent of the issue volumeThe board of Scandion Oncology proposes a rights issue to increase the commercial potential for its drug candidates and to expand its drug pipeline 2019-05-27
Upplägg7,144,590 new shares and 2,381,530 warrants of series TO 1 will be issuedSignificantly oversubscribed rights issue in Scandion Oncology 2019-07-12
Uppläggthe number of shares in Scandion Oncology will amount to 19,052,241 sharesSignificantly oversubscribed rights issue in Scandion Oncology 2019-07-12
UppläggNumber of shares before the unit issue: 11,907,651 shares.Scandion Oncology A/S publishes prospectus in connection with rights issue 2019-06-17
Uppläggsubscription commitments of approximately SEK 18.9 millionScandion Oncology A/S publishes prospectus in connection with rights issue 2019-06-17

Datum: 23 oktober 2018Typ: Nyemission vid noteringSökt: 26Tillfört: 26Teckningskurs: 5,85 SEKGaranti: ej angivet

Sökt: 26 MSEK
Tillfört: 26 MSEK
Teckningskurs: 5,85 SEK per aktie
Emissionskostnad: 2,2 MSEK

Nyemission före noteringen på Spotlight Stock Market (första handelsdag 2018-11-08), öppen för allmänheten med teckning 4-18 oktober 2018. Tecknades till cirka 104,7 MSEK (inklusive förhandsteckningar på cirka 18,5 MSEK), alltså över fyra gånger, och det högsta antalet nya aktier, 4 444 444, emitterades. Antalet aktier ökade från 7 463 207 till 11 907 651. Meddelandet finns inte i bolagets arkiv hos MFN; texten är hämtad ur kopian hos Spotlight Stock Market (publicerad 2018-10-23 09:26:42).

Ej angivet i källan: varav kvittning, garanti. Inte undersökt: finansiell rådgivare, emissionsinstitut.

Källor och citat (2 källor)

Datum2018-10-23 09:26:42Scandion Oncology A/S new share issue oversubscribed 2018-10-23
Typnew share issue begins, prior to planned listing on Spotlight Stock MarketThe subscription period for Scandion Oncology A/S new share issue begins today 2018-10-04
Sökt beloppnew share issue of approx. SEK 26 million prior to listing on Spotlight Stock MarketScandion Oncology A/S new share issue oversubscribed 2018-10-23
TillförtScandion Oncology will receive SEK 25,999,997.40 before costsScandion Oncology A/S new share issue oversubscribed 2018-10-23
TeckningskursIssue price: SEK 5.85 per shareThe subscription period for Scandion Oncology A/S new share issue begins today 2018-10-04
Emissionskostnadbefore costs of approx. SEK 2.2 million related to the issueScandion Oncology A/S new share issue oversubscribed 2018-10-23
Uppläggthe maximum number of new shares, 4,444,444 in total, will be issuedScandion Oncology A/S new share issue oversubscribed 2018-10-23
Uppläggthe total number of shares will amount to 11,907,651 sharesScandion Oncology A/S new share issue oversubscribed 2018-10-23
UppläggNumber of shares before the issue: 7,463,207 shares.The subscription period for Scandion Oncology A/S new share issue begins today 2018-10-04

"Ej angivet" betyder att källan är läst och inte säger det. "Inte undersökt" betyder att ingen har letat än. Garanter namnges bara när de är värdepappersbolag med tillstånd från Finansinspektionen eller hör till ett analyshus eller dess koncern.

Alla publiceringar

Den senaste först (de 10 senaste visas, resten fälls ut). Varje rubrik länkar till originalet hos analytikern.

2024-11-12 Redeye Scandion Oncology Q3 2024 - Searching for a partner
2024-08-29 Redeye Scandion Oncology Q2 2024 - Partnership represents best hope
2024-05-27 Redeye Scandion Oncology Q1 2024 - Funding for CORIST part 3 extension
2024-03-01 Redeye Scandion Oncology Q4 2023 - Striving towards randomised controlled data
2023-11-22 Redeye Scandion Oncology Q3 2023 - Intriguing CORIST part 2 data
2023-08-23 Redeye Scandion Oncology Q2 2023 - CORIST part 3 data around the corner
2023-05-26 Redeye Scandion Oncology Q1 2023 - Progressing towards CORIST readouts
2023-02-22 Redeye Scandion Oncology Q4 2022 - Some stability has returned
2022-11-16 Redeye Scandion Oncology Q3 2022 - Back to the basics
2021-11-29 Redeye Scandion Oncology - Resistance is Futile
2021-05-17 Redeye Redeye Initiates Coverage of Scandion Oncology

← Alla bolag